B-lymphoblastic lymphoma presenting as a primary breast mass with periductal invasion

B-lymphoblastic lymphoma is a neoplasm of immature B cells and is characterized by aggressive behavior and disease progression. Common sites of involvement are skin, lymph nodes, bone, soft tissues, breast, and the mediastinum. Gastrointestinal lesions are rarely encountered and therefore not fully described. We herein report the case of a 28-year-old male, who presented with abdominal pain and CT scan showed a tumor involving the small bowel and its mesentery. He underwent emergency laparotomy and enterectomy. Histopathology report revealed B-lymphoblastic lymphoma affecting the small bowel and the adjacent mesentery. This is the first documented case of a small bowel tumor diagnosed as B-lymphoblastic lymphoma in published literature.

Download Full-text

Amplification of ERG/ETS genes is a recurrent evolutionary event in myeloid malignancies and distinct from iAMP21 in B-lymphoblastic lymphoma

Molecular Genetics and Metabolism ◽

10.1016/s1096-7192(21)00157-8 ◽

2021 ◽

Vol 132 ◽

pp. S49-S50

Author(s):

Efrain Gutierrez-Lanz ◽

Winston Lee ◽

David McClintock ◽

May Chan ◽

Lina Shao

Keyword(s):

Lymphoblastic Lymphoma ◽

Myeloid Malignancies ◽

Evolutionary Event ◽

B Lymphoblastic Lymphoma ◽

Ets Genes

Download Full-text

An Unsuspected Finding of t(9;22): A Rare Case of Philadelphia Chromosome-Positive B-Lymphoblastic Lymphoma

Case Reports in Hematology ◽

10.1155/2017/2413587 ◽

2017 ◽

Vol 2017 ◽

pp. 1-4 ◽

Cited By ~ 3

Author(s):

Prajwal Boddu ◽

C. Cameron Yin ◽

Rashmi Kanagal-Shamanna ◽

Guillin Tang ◽

Beenu Thakral ◽

...

Keyword(s):

Bone Marrow ◽

Kinase Inhibitors ◽

Bone Marrow Involvement ◽

Philadelphia Chromosome ◽

Lymphoblastic Lymphoma ◽

Accurate Diagnosis ◽

Biopsy Specimens ◽

B Lymphoblastic Lymphoma ◽

Prophylactic Chemotherapy

While rare, cases of isolated extramedullary disease of B-cell Lymphoblastic Lymphoma (B-LBL) without morphologic bone marrow involvement have been described. In this report, we illustrate the case of an elderly gentleman who presented with isolated testicular and vertebral LBL involvement but had no morphologic bone marrow involvement. The initial plan of treatment was to treat along the lines of Philadelphia negative B-ALL/LBL. During this time, fluorescence in situ hybridization (FISH) and PCR testing for BCR-ABL1 rearrangements were being performed on the marrow specimens as a part of routine diagnostic workup. While the FISH returned negative, PCR testing unexpectedly detected BCR-ABL1 fusion transcripts at a low level of 0.48%. Given their presence, we performed FISH for BCR/ABL1 rearrangement in both testicular and L5 vertebral specimens which were 80–90% positive. He subsequently received rituximab, hyper-CVAD, and dasatinib, along with prophylactic intrathecal prophylactic chemotherapy. The patient achieved a prolonged remission but eventually relapsed, 4 years later. Had it not been for this fortuitous discovery, the patient would not have been treated with tyrosine kinase inhibitors. We emphasize that FISH and PCR testing for BCR-ABL1 rearrangement are integral to arriving at an accurate diagnosis and should be routinely tested on B-LBL biopsy specimens.

Download Full-text

CNS relapse of B-lymphoblastic lymphoma after allogeneic hematopoietic stem cell transplantation: therapy with donor CD19-specific CAR-T cells

Pediatric Hematology/Oncology and Immunopathology ◽

10.24287/1726-1708-2021-20-2-143-147 ◽

2021 ◽

Vol 20 (2) ◽

pp. 143-147

Author(s):

O. O. Molostova ◽

L. N. Shelikhova ◽

D. E. Pershin ◽

A. M. Popov ◽

M. E. Dubrovina ◽

...

Keyword(s):

T Cells ◽

Stem Cell ◽

Hematopoietic Stem Cell Transplantation ◽

Stem Cell Transplantation ◽

Cell Transplantation ◽

Lymphoblastic Lymphoma ◽

Hematopoietic Stem ◽

Car T Cells ◽

Car T ◽

B Lymphoblastic Lymphoma

Presently, there is no consensus on the best treatment for relapsed B-cell acute lymphoblastic leukemia/lymphoma after allogeneic hematopoietic stem cell transplantation (allo-HSCT), particularly in patients with extramedullary lesions. There are certain anti-tumor drugs that can be used in case of relapse after allo-HSCT, however, prospective randomized studies directly comparing different chemotherapy and immunotherapy approaches are generally lacking. Retrospective studies exploring therapy for relapsed disease are difficult to compare due to the inhomogeneity of patient populations and the diversity of treatment approaches. In such situations, the treatment choice is influenced by the characteristics of the tumor population, particularly, its immunophenotype, available drugs, and the experience of a healthcare facility and physicians. This clinical case report describes the process of treating a patient with B-lymphoblastic lymphoma and shows the possibility of using donor CD19-specific CAR-T cells as a treatment for isolated CNS relapse after allo-HSCT. The patient's parents gave their consent to the use of their child's data, including photographs, for research purposes and in publications.

Download Full-text